GMAB — Genmab A/S

Genmab Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Increased by 25% year-over-year, driven by strong sales of EPKINLY and royalties from DARZALEX and Kesimpta.
• Product Sales: EPKINLY sales reached $137 million, up 52% year-over-year; Tivdak sales were $39 million, an 18% increase.
• Operating Profit: Grew by 23%, reflecting disciplined investments in R&D and commercialization.
• Tax Expense: Approximately $21 million, with an effective tax rate of 28.9%. Future volatility in this rate is anticipated due to the integration of Merus operations.
• Financial Guidance: Expected total revenue growth of 14% for 2026, with operating expenses projected between $2.7 billion and $2.9 billion.

2. Strategic Updates and Business Highlights

• Product Development:
  • EPKINLY's label was updated to remove hospitalization requirements, potentially increasing its uptake in outpatient settings.
  • Rina-S is progressing with two new Phase III trials planned in ovarian and endometrial cancers, with completed enrollment in the pivotal RAINFOL-02 trial.
  • The integration of Merus is on track, with a focus on leveraging petosemtamab's potential.
• Market Expansion: Strong performance in both established and new markets, particularly for EPKINLY and Tivdak, with ongoing efforts to enhance patient access in Europe.

3. Forward Guidance and Outlook

• 2026 Outlook: The company is optimistic about sustaining momentum, expecting multiple data readouts that could support product launches in 2027.
• Pipeline Development: Continued investment in late-stage assets, with a focus on maximizing the potential of EPKINLY, Rina-S, and petosemtamab.

4. Bad News, Challenges, or Points of Concern

• Increased Trial Sizes: The upsizing of the frontline petosemtamab study from 500 to 700 patients raises questions about trial dynamics, although management insists timelines remain unaffected.
• Competitive Landscape: Increased competition in the bispecific and ADC markets, particularly in gynecological cancers, poses a risk to market share and pricing power.
• Regulatory Uncertainty: While the FDA has shown flexibility in approving therapies without OS benefits, demonstrating significant PFS improvements remains crucial for commercial success.

5. Notable Q&A Insights

• Trial Enrollment: Management confirmed that the increased patient size for the petosemtamab trial will not require additional sites and that enrollment has exceeded expectations.
• EPKINLY's Competitive Edge: Physicians are optimistic about EPKINLY's potential as a first-line treatment, citing its unique mechanism of action and favorable safety profile.
• Data Readouts: Management remains committed to providing timely updates on trial results, with expectations for significant data releases later in 2026.
• Market Dynamics: Discussions highlighted the importance of outpatient treatment settings and the role of bispecifics in earlier lines of therapy, which could influence physician prescribing patterns.

Overall, Genmab's Q1 2026 results reflect strong growth and strategic positioning, although challenges related to competition and trial dynamics warrant close attention.